Findx
EnglishEnglish
Dansk Dansk

Valerio Therapeutics Société anonyme stock analysis ALVIO.FR

Valerio Therapeutics is a biotechnology company based in Villejuif, France, that today focuses its core operations entirely on early‐stage drug discovery and preclinical research rather than clinical trials. Its principal business consists of developing proprietary technology platforms - V-Body and integrated chemistry - that enable creation of novel therapeutic candidates, particularly precision-guided modalities. It has discontinued all clinical stage operations, including its lead clinical trial (VIO-01), and closed its U.S. office to redirect resources toward discovery and partnership readiness.

The V-Body platform is centered on synthetic humanized single-domain antibodies (sdAbs, approximately 15 kilodaltons in size) intended to serve as biological vectors. These sdAbs are engineered for multiple therapeutic formats, including antibody-drug conjugates (ADCs), CAR-T sdAbs, V-Body - oligonucleotide conjugates, and T cell engagers, with target indications in rare diseases, autoimmune, inflammatory, and oncology fields. The integrated chemistry platform supports the development effort by providing linker/payload technologies, bioconjugation, stabilization, formulation, and hybrid molecule design, with the overall aim of generating preclinical proof‐of‐concept candidates ready for partnerships or licensing.

Valerio Therapeutics' business model now emphasizes technology/platform development and collaborative partnering rather than in-house clinical development. The company uses its V-Body and chemistry platforms to attract non-dilutive funding, exclusive licenses, and R&D collaborations. Markets it addresses include oncology; immune-mediated inflammatory disease; autoimmunity; rare and genetic diseases. R&D and discovery are centralized in France, especially through its subsidiary Valour Bio, which absorbed acquisition of Emglev Therapeutics and serves as the hub for V-Body platform activities, including library optimization and preclinical candidate selection.

Healthcare · Biotechnology · Biotechnology · France
Quality
Quality
Momentum
Momentum
Strength
Strength
Entry
Entry: Not yet
A short-term bounce, not yet a trend change. Price is above SMA 20, but the moving averages are still falling, so being above them reflects a bounce inside a downtrend rather than a reversal. Wait for the averages to flatten and turn up before entering.
Trend
Trend: Trend broken
Trend broken. Two or more consecutive closes below SMA 50 signal that the medium-term trend has flipped. Exiting here is the rule rather than the exception.
‹
›

Click to see warnings

Neg. values
‹
›
Years
Lower P/E (Bear)
Sign in to view
Fair Value
Sign in to view
Upper P/E (Bull)
Sign in to view
Analysts
Sign in to view
Price: Financials: Q2 FY2026 / FY2025TTM presentEstimates: UnavailableScored as: Standard companyEvidence: LimitedDetails

Freshness

  • Price through:
  • Latest annual period: FY2025 (); filed
  • Latest interim period: Q2 FY2026 (); filed
  • TTM period: ; used by: Quality, Strength
  • No future Diluted EPS estimate is available.
  • Target price: Date unknown, Analyst count unknown

Scoring profile

Effective scoring profile: Standard company

Report a suspected classification error

Score evidence

Quality: Score calculated; High confidence; TTM used
Business Momentum: Score calculated; Good confidence; TTM not used
Strength: Score calculated; Limited confidence; TTM used
  • Limited confidence for Strength by model design: some checks rest on only three or four full fiscal years; diluted EPS stood in for normalized EPS.

Sources and adjustments

Remaining score inputs are provider supplied.

  • Debt to operating cash flow: derived by Findx
  • Net debt to EBITDA: derived by Findx

Key stock metrics

Blended P/E  :
P/E (last full year) :
N/A
N/A
Blended EPS  :
EUR N/A
Blended EPS Yield  :
N/A
Dividend Yield :
(Trailing 12 months)
0.00%
Buyback Yield :
(Trailing 12 months)
-0.02%
Market Cap:EUR 226.25 M

Valuation basis

Analyst price target
Yearly EPS growth  :
( years incl. estimates)
N/A

P/E Values

Upper P/E:
Fair Value P/E  :
Lower P/E:
Market P/E  :

EPS Estimates

:
N/A
:
N/A
:
N/A

About Valerio Therapeutics Société anonyme

Description, revenue sources, strengths and weaknesses

DESCRIPTION

Valerio Therapeutics is a biotechnology company based in Villejuif, France, that today focuses its core operations entirely on early‐stage drug discovery and preclinical research rather than clinical trials. Its principal business consists of developing proprietary technology platforms - V-Body and integrated chemistry - that enable creation of novel therapeutic candidates, particularly precision-guided modalities. It has discontinued all clinical stage operations, including its lead clinical trial (VIO-01), and closed its U.S. office to redirect resources toward discovery and partnership readiness.

The V-Body platform is centered on synthetic humanized single-domain antibodies (sdAbs, approximately 15 kilodaltons in size) intended to serve as biological vectors. These sdAbs are engineered for multiple therapeutic formats, including antibody-drug conjugates (ADCs), CAR-T sdAbs, V-Body - oligonucleotide conjugates, and T cell engagers, with target indications in rare diseases, autoimmune, inflammatory, and oncology fields. The integrated chemistry platform supports the development effort by providing linker/payload technologies, bioconjugation, stabilization, formulation, and hybrid molecule design, with the overall aim of generating preclinical proof‐of‐concept candidates ready for partnerships or licensing.

Valerio Therapeutics' business model now emphasizes technology/platform development and collaborative partnering rather than in-house clinical development. The company uses its V-Body and chemistry platforms to attract non-dilutive funding, exclusive licenses, and R&D collaborations. Markets it addresses include oncology; immune-mediated inflammatory disease; autoimmunity; rare and genetic diseases. R&D and discovery are centralized in France, especially through its subsidiary Valour Bio, which absorbed acquisition of Emglev Therapeutics and serves as the hub for V-Body platform activities, including library optimization and preclinical candidate selection.

ADDITIONAL INFO

It is very important that you understand this

Fair Value is an estimate, and you choose the basis it is built on. Do not invest based on our default without understanding how we calculate it.